The Pandemic Threat and Prospects for H5N1 Vaccination 10th Beijing Hong Kong Medical Exchange Update on Respiratory Medicine - Acetamides - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2013-05-09 06:29:32 Health Biology Vaccines Acetamides Neuraminidase inhibitors Influenza treatment Transmission and infection of H5N1 Cytokine storm Zanamivir Influenza Epidemiology Influenza A virus subtype H5N1		The Pandemic Threat and Prospects for H5N1 Vaccination 10th Beijing/Hong Kong Medical Exchange Update on Respiratory Medicine Add to Reading List Source URL: www.hkma.org Download Document from Source Website File Size: 284,65 KB Share Document on Facebook

	Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach DocID: 1vb6O - View Document
	FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A - Company Plans to Initiate Phase 2b Clinical Trial in Early 2018 Cambridge, MA – November 1, 2017 – Vi DocID: 1uP0v - View Document
	Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach DocID: 1uOXA - View Document
	XOFLUZATM (Baloxavir Marboxil) Tablets 10mg/20mg Approved for the Treatment of Influenza Types A and B in Japan Osaka, Japan, February 23, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, DocID: 1uL4E - View Document
	January 14, 2015 LACDPH Health Update: ACCESS TO ANTIVIRAL MEDICATION FOR TREATMENT OF INFLUENZA This message is intended for pharmacies and healthcare facilities as well as emergency medicine, internal medicine, urgent DocID: 1rZMZ - View Document